34. Ajovy


Active ingredient: fremanezumab  
Disease: migraine  
Peak sales estimate: $500 million  
Approved: Sept. 14  
Company: Teva Pharmaceutical Industries  

The scoop: In September, Teva’s Ajovy became the second drug in the new CGRP inhibitor class to secure an approval, following Amgen and Novartis’ Aimovig into the field. After the Amgen/Novartis team set their price at $6,900 per year, Teva followed suit. An injection given monthly or quarterly to prevent migraines, Ajovy could reach peak sales of more than $500 million, according to analysts. Its approval comes at a good time, as it gives the drugmaker a growth driver while Teva works through a turnaround and loss of exclusivity for multiple sclerosis blockbuster Copaxone. Ajovy has already had one setback since approval as Express Scripts opted against giving the drug preferential coverage in its formulary. For Teva, the approval comes amid a major turnaround underway by CEO Kåre Schultz, including a massive round of layoffs and downsizing. — Eric Sagonowsky 

34. Ajovy

Suggested Articles

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.

The bispecific outperformed J&J’s blockbuster against an endpoint that tracked the proportion of patients achieving a 90% reduction in psoriasis,